News
Positive stool test after colonoscopy associated with increased cancer risk
Read the study published in Clinical Gastroenterology and Hepatology, co-authored by Dr. Jennifer Telford, medical director of the BC Cancer Colon Screening Program, analyzing data from the BC Colon Screening Program.
New national survey study aims to improve equity in Canadian cancer clinical trials
A new Canadian Cancer Trials Group (CCTG) survey study, SC32S, has opened across Canada to collect sociodemographic data from cancer clinical trial participants and assess whether asking questions about this information feels appropriate to patients. The patient survey will ask CCTG trial participants about different parts of everyday life that can affect patient health and experience with cancer care.
PR21 secondary analysis explores treatment sequencing in advanced prostate cancer trial
Read the Canadian Cancer Trials Group story on results from a pre-planned secondary analysis of the PR21 PLUDO trial.
BC Cancer investigators participate in CCTG VISION Leadership Program
Three BC Cancer clinical investigators are participating in the Canadian Cancer Trials Group (CCTG) VISION – Investigator Leadership Training Program, a new education and mentorship initiative focused on developing leadership skills among current and emerging clinical trialists.
Drs. Leah Lambert, Jonathan Loree and Lucia Nappi are part of the inaugural VISION cohort.
BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.